ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.503,80
-0,52%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08996
0,00%
Bitcoin
63.367,36
-2,29%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ASLAN Pharmaceuticals Ltd (ASLN)

  7. ASLAN Pharmaceuticals Ltd (ASLN) News

ASLN

ASLAN Pharmaceuticals (ASLN)

ASLAN Pharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ASLN
DatumZeitQuelleÜberschriftSymbolFirma
27/08/201912h00GlobeNewswire Inc.New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual MeetingNASDAQ:ASLNASLAN Pharmaceuticals Ltd
14/08/201914h44Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
13/08/201910h03GlobeNewswire Inc.ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:ASLNASLAN Pharmaceuticals Ltd
31/07/201910h14GlobeNewswire Inc.ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology CongressNASDAQ:ASLNASLAN Pharmaceuticals Ltd
29/07/201912h11Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/07/201910h20GlobeNewswire Inc.ASLAN Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of ChairmanNASDAQ:ASLNASLAN Pharmaceuticals Ltd
28/06/201922h29Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/06/201912h08Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/06/201912h08Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
17/06/201922h06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
17/06/201915h15Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
10/06/201912h34Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
04/06/201914h00GlobeNewswire Inc.ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic DermatitisNASDAQ:ASLNASLAN Pharmaceuticals Ltd
31/05/201912h12Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
31/05/201909h15GlobeNewswire Inc.ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSLNASDAQ:ASLNASLAN Pharmaceuticals Ltd
10/05/201910h15GlobeNewswire Inc.ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric CancerNASDAQ:ASLNASLAN Pharmaceuticals Ltd
30/04/201912h28Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
29/04/201915h36Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
29/04/201911h02GlobeNewswire Inc.ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:ASLNASLAN Pharmaceuticals Ltd
02/04/201912h17Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
29/03/201910h50GlobeNewswire Inc.ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic DermatitisNASDAQ:ASLNASLAN Pharmaceuticals Ltd
25/03/201911h09Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
22/03/201912h25GlobeNewswire Inc.ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateNASDAQ:ASLNASLAN Pharmaceuticals Ltd
12/03/201912h08Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
27/02/201912h12Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
26/02/201923h35GlobeNewswire Inc.ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South KoreaNASDAQ:ASLNASLAN Pharmaceuticals Ltd
15/02/201917h02Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
30/01/201912h07Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:ASLNASLAN Pharmaceuticals Ltd
29/01/201923h40GlobeNewswire Inc.ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate RestructuringNASDAQ:ASLNASLAN Pharmaceuticals Ltd
23/01/201907h35GlobeNewswire Inc.ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell LinesNASDAQ:ASLNASLAN Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:ASLN

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
AMEX
XLE
Energy Select Sector SPDR
DBI
MDAX
MDAX
DBI
TDXP
Tec DAX
USOTC
ADDYY
Adidas (QX)
COIN
SOLUSD
Solana
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
FX
EURGBP
Euro vs Sterling
TG
CBK
Commerzbank
TG
D7G
Nel ASA
TG
ALV
Allianz
TG
LHA
Deutsche Lufthansa
TG
432
Arbor Metals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten